Abstract

Sensors employing elastomers enhanced with electrically conductive 2D nanoparticles are provided. The nanoparticles are formed by applying shear to layered materials present in elastomer precursors (e.g., elastomeric monomer(s) and/or curing agent(s)). Subsequent exfoliation of the layers occurs directly within the precursor and/or curing agent. The cured elastomer nanocomposites can be employed for electrochemical sensing, flexible touchpads, pressure sensors, and wireless sensors, amongst other applications.

IPC Classes  ?

• H01B 1/20 - Conductive material dispersed in non-conductive organic material
• B01F 23/50 - Mixing liquids with solids
• B01F 23/53 - Mixing liquids with solids using driven stirrers
• B01F 23/70 - Pre-treatment of the materials to be mixed
• B01F 27/232 - Mixers with rotary stirring devices in fixed receptaclesKneaders characterised by the orientation or disposition of the rotor axis with two or more rotation axes
• B01F 101/00 - Mixing characterised by the nature of the mixed materials or by the application field
• C08J 3/22 - Compounding polymers with additives, e.g. colouring using masterbatch techniques
• C08K 9/00 - Use of pretreated ingredients
• G01L 1/14 - Measuring force or stress, in general by measuring variations in capacitance or inductance of electrical elements, e.g. by measuring variations of frequency of electrical oscillators
• G01L 1/22 - Measuring force or stress, in general by measuring variations in ohmic resistance of solid materials or of electrically-conductive fluidsMeasuring force or stress, in general by making use of electrokinetic cells, i.e. liquid-containing cells wherein an electrical potential is produced or varied upon the application of stress using resistance strain gauges
• G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells
• G06F 3/0354 - Pointing devices displaced or positioned by the userAccessories therefor with detection of 2D relative movements between the device, or an operating part thereof, and a plane or surface, e.g. 2D mice, trackballs, pens or pucks

Abstract

Provided for herein are novel recombinant polypeptides comprising endogenous signal peptides targeting the nucleus of a cell and a payload protein, nucleic acid molecules encoding the same, pharmaceutical compositions comprising the same, and methods of use thereof.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Provided for herein are novel signal peptides that direct an encoded protein to the nucleus of a cell, recombinant polypeptides comprising the same, nucleic acid molecules encoding the same, pharmaceutical compositions comprising the same, and methods of use thereof.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Suture tensioning systems, methods, and devices include a suture device for extracting a suture thread from a patient and then determining a location to secure the suture knot based on a balanced tension measurement. The suture device has a needle pass mount with needle passes, and a slidable eyelet assembly positioned opposite the needle passes. The eyelet assembly includes gripping portions for moving the eyelet assembly relative to other components of the suture device. Accordingly, eyelets extending from the eyelet assembly move through the needle pass mounts and extend out the needle passes. With the suture thread secured in the extended eyelet, the eyelet assembly is retracted. The suture thread is attached to a tensioning bar and tension meter. The tension meter indicates if the suture tension is within a threshold range and comparable to the opposite side, and a precise tying location for the suture knot is determined.

IPC Classes  ?

• A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
• A61B 17/00 - Surgical instruments, devices or methods
• A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents

Abstract

Systems and methods to determine an increased likelihood of a neurological disorder based on a dorsal surface texture of the medulla oblongata. The method includes selecting, using a computational topography software, a region of interest (ROI) within a diameter ring at a lower dorsal posterior medulla encompassing a region of a clava. The method includes analyzing, using the computational topography software, surface complexity of the ROI using a metric maximum curvature analysis that provides a local maximum curvature on discretized triangular mesh surface representations. The method includes determining between introverted triangles and extroverted triangles and calculating a first number of the introverted triangles and a second number of the extroverted triangles in the ROI. The method also includes the determination of the presence or absence of a distinct spatial dissemination pattern of introverted triangles extending craniocaudally within a center of the ROI.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 7/64 - Analysis of geometric attributes of convexity or concavity
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Provided herein are compounds comprising a therapeutic molecule conjugated to a beta cell targeting motif, that can specifically deliver therapeutic molecules to the pancreas. Also provided herein are methods of making and using these compounds for the treatment of pancreatic diseases.

Abstract

Provided for herein are novel recombinant polypeptides comprising endogenous mitochondria targeting signal peptides and a payload protein, nucleic acid molecules encoding the same, pharmaceutical compositions comprising the same, and methods of use thereof. In some embodiments, the recombinant polypeptide comprises a formula of X1-(Y l)a-Zl, wherein XI is an endogenous signal peptide, Y1 is a peptide linker, and Z1 is a payload protein, wherein a is an integer selected from 0 and 1.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 4/12 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from animalsPeptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from humans
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

Provided for herein are novel mitochondria targeting signal peptides, recombinant polypeptides comprising the same, nucleic acid molecules encoding the same, pharmaceutical compositions comprising the same, and methods of use thereof.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present invention relates to novel small molecule of Formula I, and the preparation and use thereof: Formula (I).

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• C07D 209/04 - IndolesHydrogenated indoles
• C07D 231/10 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
• C07D 233/54 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
• C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 263/30 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
• C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
• C07D 277/20 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
• C07D 333/04 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulfur atom
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 31/14 - Antivirals for RNA viruses
• A61P 35/00 - Antineoplastic agents

Abstract

Provided for herein are novel recombinant polypeptides comprising endogenous secretory signal peptides and a payload protein, nucleic acid molecules encoding the same, pharmaceutical compositions comprising the same, and methods of use thereof.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 19/00 - Hybrid peptides
• C07K 14/76 - Albumins
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Provided for herein are novel secretory signal peptides, recombinant polypeptides comprising the same, nucleic acid molecules encoding the same, pharmaceutical compositions comprising the same, and methods of use thereof.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Compositions and methods for treating a tumor by targeting STING signaling are provided. Embodiments of the present disclosure also provide methods for determining suitability of a candidate for an immunotherapy and/or for evaluating prognosis of an immunotherapy.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61P 35/00 - Antineoplastic agents
• C08G 64/18 - Block or graft polymers
• C08G 65/333 - Polymers modified by chemical after-treatment with organic compounds containing nitrogen
• C12P 19/36 - Dinucleotides, e.g. nicotineamide-adenine dinucleotide phosphate
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Described herein are methods and systems for identifying and/or treating subjects having cancer who are more likely to respond to treatment with an inhibitor of the transcription factor HIF-2α.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61P 35/00 - Antineoplastic agents
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G16B 25/00 - ICT specially adapted for hybridisationICT specially adapted for gene or protein expression
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G16B 25/20 - Polymerase chain reaction [PCR]Primer or probe designProbe optimisation
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

Compositions and methods for treating a tumor by targeting STING signaling are provided. Embodiments of the present disclosure also provide methods for determining suitability of a candidate for an immunotherapy and/or for evaluating prognosis of an immunotherapy.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 31/708 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
• A61K 38/21 - Interferons
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C08G 64/18 - Block or graft polymers

Abstract

This technology relates to polynucleotides comprising optimized FMR1 open reading frame (ORF) sequences, viral vectors comprising the same, and methods of using the same for delivery of the ORF to a cell or a subject and to treat disorders associated with aberrant expression of FMR1, such as Fragile X syndrome (“FXS”).

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/86 - Viral vectors

Abstract

The present disclosure generally relates to compositions and methods that involve the use Enantiomer-Testosterone (Ent-Testosterone). The disclosed Ent-Testosterone can be used to inhibit quorum sensing in bacteria. The disclosure further compositions and method for treating a subject with bacterial infection or a condition complicated by colonization of bacteria.

IPC Classes  ?

• A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
• A61P 31/04 - Antibacterial agents

Goods & Services

Downloadable computer software and hardware sold together as a unit for purposes of locating, gathering, compiling, analyzing, modeling, graphing, visualizing, and sharing patient records and data and healthcare provider actions for use in connection with patient monitoring; downloadable computer software and hardware sold together as a unit for use in connection with patient monitoring equipment for receiving, processing, transmitting, and displaying data; downloadable computer software and hardware sold together as a unit for use in connection with controlling and managing patient medical information; downloadable computer software and hardware sold together as a unit for use in connection with managing patient care and directing healthcare provider interventions; downloadable computer software for purposes of locating, gathering, compiling, analyzing, modeling, graphing, visualizing, and sharing patient records and data and healthcare provider actions for use in connection with patient monitoring; downloadable computer software for use in connection with patient monitoring equipment for receiving, processing, transmitting, and displaying data; downloadable computer software for use in connection with controlling and managing patient medical information; downloadable computer software for use in connection with managing patient care and directing healthcare provider interventions

Abstract

A novel framework to transform a T-cell receptor (TCR) repertoire sample into a fixed-length vector. Short peptide sequences with different lengths in each TCR may be encoded into a numeric vector with fixed dimensions. A large amount of existing TCRs from healthy individuals may be pooled to generate a distribution of the encoding vector in a high-dimensional Euclidean space. Unsupervised clustering may be performed on the “points” in this space (each point is a TCR) to group them into antigen-specific clusters. The centroid of each cluster may be defined as a repertoire functional unit (“RFU”). For a new TCR repertoire sample, each TCR may be assigned to its most similar RFU group, and the RFU counts may be normalized by the number of sequences in the repertoire. The output data may be a fixed-length RFU vector, with each number representing the relative abundance of the given RFU in the repertoire.

IPC Classes  ?

• G16B 40/30 - Unsupervised data analysis
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection

Abstract

Methods for correcting one or more image aberrations in an electron microscopy image, including cryo-EM images, are provided. The method includes obtaining a plurality of electron microscope (EM) images of an internal reference grid sample having one or more known properties, the plurality of electron microscope images obtained for a plurality of optical conditions and for a plurality of coordinated beam-image shifts. The method may also include, among other features, determining an aberration correction function that predicts aberrations for every point in the imaged area using kernel canonical correlation analysis (KCCA).

IPC Classes  ?

• G06T 5/80 - Geometric correction
• H01J 37/22 - Optical or photographic arrangements associated with the tube

Abstract

In some aspects, the present disclosure provides methods for generating CAR T cells in situ. The present disclosure provides lipid nanoparticles that selectively target a spleen cell, in particular, a lymphocyte such as a T cell. The lipid nanoparticle provided herein contain a five component composition that includes a permanently anionic lipid giving the lipid nanoparticle an apparent pKa of less than 6.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

In some aspects, the present disclosure provides a nanoparticle composition comprising tRNA and an aminolipid delivery compound. The aminolipid delivery compound may be a dendrimer, dendron, or dendritic lipid, a polymer such as a polyamide or polyester, or a lipid with one or more hydrophobic components. In some embodiments, these compositions may be administered to a patient to treat a genetic disease or disorder such as cystic fibrosis, Duchene muscular dystrophy, or cancer.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

An imaging system configured to transform a lateral scan motion into axial refocusing, thus enabling aberration free remote focusing. In one embodiment, the imaging system provides aberration free remote focusing by causing a beam of light to be scanned over a stationary mirror having a variable height in the scan direction, thereby causing the beam of light to be defocused in an axial direction in the return direction (e.g., the direction of propagation for the reflected beam of light). By configuring the back-reflected light resulting from the lateral scan component as described herein, a pure axial scan motion may be obtained at the rate of the employed (lateral) scanning technology (e.g., a GSM). This capability allows the imaging system of the present inventive concept to leverage rapid lateral scan technologies to produce rapid axial displacement of the axial focus of the beam of light.

IPC Classes  ?

• G02B 21/06 - Means for illuminating specimen
• G02B 21/36 - Microscopes arranged for photographic purposes or projection purposes
• H04N 23/56 - Cameras or camera modules comprising electronic image sensorsControl thereof provided with illuminating means
• H04N 23/74 - Circuitry for compensating brightness variation in the scene by influencing the scene brightness using illuminating means

Abstract

Provided herein are nucleic acid inhibitors or activators that impact the expression, levels or activity of SNORA13 in a cell. Also provided are pharmaceutical compositions for using these activators and inhibitors for the treatment of ribosomopathies, cancer, and senescence-associated pathologies.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 35/00 - Antineoplastic agents

Abstract

Pharmaceutical compositions comprising hydrogen bonded organic framework (HOF) molecules and a drug are provided herein. Drug release from the HOF can be induced using ultrasound such as focused ultrasound (FUS). Methods of ultrasonic drug delivery using a HOF are provided herein and can be used to treat a variety of diseases.

IPC Classes  ?

• C07C 63/331 - Polycyclic acids with all carboxyl groups bound to non-condensed rings
• C07C 237/30 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
• C07D 253/02 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group not condensed with other rings
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents

Abstract

The disclosure provides a lipid nanoparticle (LNP) composition comprising a polynucleotide, an ionizable lipids, a quaternary ammonium lipid at a molar percentage from about 20% to about 65%, a phospholipid, a cholesterol, and a PEG-lipid and method of using the LNP.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 35/00 - Antineoplastic agents

Abstract

Methods of treating or preventing a respiratory disease or condition in a subject in need thereof, inflating the lungs of a subject in need thereof, and reducing the positive-end expiratory pressure (PEEP) needed for mechanical ventilation, the methods comprising administering an effective amount of a composition comprising one or more perfluorocarbons to the subject.

IPC Classes  ?

• A61K 33/16 - Fluorine compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present disclosure generally relates to antibodies or fragments thereof that bind to Protocadherin 7(PCDH7). The disclosure further provides amino acid sequences and nucleic acid sequences encoding the antibodies. Also provided are compositions and methods for use in treatment of cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

Compounds, compositions, and methods for making and using the compounds for treatment of cardiovascular or cholesterol related disorder diseases caused by mutations in UBIAD1 are provided herein. Mechanistically, these compounds were found to be allosteric activators of UBIAD1 gene and enhance its affinity for GGpp.

IPC Classes  ?

• C07D 213/04 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
• C07C 233/07 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid

Abstract

Provided herein are single domain antibodies (sdAbs) having a specific affinity for a rare heparan sulfate moiety which can be used to disrupt DC-HIL function to reduce and prevent cancer progression and metastasis. Compositions and methods of use thereof are also provided for use of these sdAbs to treat cancer and cancer metastasis in a subject in need thereof.

IPC Classes  ?

• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

The disclosure relates to compositions and methods for providing neuroprotection in a subject and for treating neurodegenerative diseases and traumatic brain or spinal injuries. In embodiments, the disclosure provides agents that bind to cytoplasmic heterogeneous nuclear ribonucleoprotein (hnRNP) in neurons and that can inhibit neuronal cell death.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present disclosure provides methods and compositions for the treatment of glycogen storage disorders, such as, for example, Lafora Disease and adult polyglucosan body disease. The methods and compositions of the present disclosure comprise isolated nucleic acid molecules, rAAV vectors and rAAV viral vectors comprising polynucleotide sequences encoding for artificial micro RNAs (amiRNAs) directed against GYS1.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 15/86 - Viral vectors

Abstract

The present disclosure is concerned with methods of treating disorders associated with overexpression of an eyes absent (EYA) protein such as, for example, vascular disease, a fibrosis-related disorder, hearing loss, and a metabolic disease using quinazoline-2,4-diamines. Also disclosed are methods of treating cancer that comprises a tumor that overexpresses at least one eyes absent (EYA) protein (e.g., breast cancer, cervical cancer, ovarian cancer, liver cancer, pancreatic cancer, pediatric cancers). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61P 35/00 - Antineoplastic agents

Abstract

Ultra pH sensitive (UPS) micelles encapsulating cytokines are provided that provide lower toxicity and higher efficacy compositions and methods for treating cancer with those compositions.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 38/20 - Interleukins
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C08F 293/00 - Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule

Abstract

A power and/or electricity generating source and/or component that is TENG-based, and that may be configured as an assembly and/or component for powering one or more electronic devices, is disclosed, a case, carrier or other carrying container, for example a case for a cell phone, ipad, electronic tablet, personal computer, or any similar device, that provides an electricity source to power the cell phone, ipad, electronic tablet, is disclosed. The energy generating carriers and/or containers and configurations thereof, also provide an electricity energy storage source, such as a capacitor. This electronic energy storage source may be incorporated within an electronic device itself, or may be incorporated within the case and/or covering. A bridge rectifier is also provided in some embodiments of the case. Upon walking or touching a surface of an electronic device, the power generating source will harness mechanical energy, and provide for the generation of electricity with the one or more TENG components (TESTEC) that comprise the energy generating unit. Metal particles (silver, copper, etc. nanoparticles) incorporated within and/or on polymeric layers and/or a film of the carrier and/or container assembly, are also provided, and provide for enhanced energy generating capacity of the energy generating and storage components described.

IPC Classes  ?

• H02N 1/04 - Friction generators
• H04B 1/3888 - Arrangements for carrying or protecting transceivers

Abstract

The present disclosure generally relates to methods and in vitro system for generation of embryo like structures. The disclosure further provides methods for use of the embryo like structures in regenerative medicine and drug screening.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• C12N 5/095 - Stem cellsProgenitor cells
• C07C 25/13 - Monocyclic aromatic halogenated hydrocarbons containing fluorine

Abstract

Apparatus and methods for implanting an antibiotic spacer into a bone cavity. In certain embodiments, the antibiotic spacer comprises a shaft and a plurality of planar members coupled to the shaft. In particular embodiments, the plurality of planar members are configured such that the outer perimeter of each planar member can be intra-operatively modified.

IPC Classes  ?

• A61F 2/30 - Joints
• A61F 2/46 - Special tools for implanting artificial joints

Abstract

Systems, methods and program products are provided for producing, identifying and utilizing neuroimaging biomarkers that quantify brain network properties (connectomics) for the purpose of assessing alterations in network-based structure and function in a wide variety of health-related conditions including neurologic and psychiatric disorders, and normal changes across the lifespan including development and aging. One or more computers of a high-performance computing portal may obtain a selected disorder or age- associated change. A plurality of databases storing data populated from a plurality of human brain subject may be accessed. The plurality of databases may include data related to (i) a task-activation, (ii) a voxel-based morphometry, and (iii) a voxel-based physiology. A multivariate coordinate-based meta-analysis (CBMA) algorithm may be applied to the obtained information so as to associated identify human brain network properties. A virtual representation of the human brain network may be generated and presented to a user of the portal.

IPC Classes  ?

• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• G06T 7/00 - Image analysis
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

Systems, methods, and devices include a tissue measuring device for analyzing tissue laxity. The tissue measuring device includes a probe with a probe housing removably coupled to a first end of a manifold body. A sensor assembly extending from the first end of the manifold body includes a proximity sensor at a distal end, which aligns with a measurement opening in the probe housing when the probe housing is attached to the manifold body. A camera and/or light capture additional tissue data via video. The proximity sensor, the camera, and/or the light are controllable to perform the tissue laxity data collection and analysis procedures using a control console which uses one or more ramp profiles to generate the tissue laxity data. The one or more ramp profiles can include a first hold plateau, a peak, a second hold plateau, and/or a tissue release period.

IPC Classes  ?

• A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes

Abstract

Methods and systems for computer-assisted contour revision. An image slice may be selected from a medical image. The image slice may include an initial contour of a target anatomical structure in the medical image. At least a portion of the image slice and the initial contour may be displayed on a graphical user interface (GUI). Upon determining that the initial contour requires revision, a revised contour may be generated. A first input may be received from a user to the GUI to indicate a first point of revision. The medical image, the first input, and the initial contour may be input into a trained deep neural network that automatically extracts learned image characteristics. The extracted learned image characteristics may be processed using one or more deep-learning segmentation algorithms of the trained deep neural network. The revised contour may be automatically generated using the processed extracted learned image characteristics.

IPC Classes  ?

• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G06T 7/00 - Image analysis
• G06T 7/12 - Edge-based segmentation
• G06T 7/50 - Depth or shape recovery

Abstract

The present disclosure relates to compounds that modulate (i.e., regulate) proteasome activity, pharmaceutical compositions containing such compounds, and uses of these compounds and compositions for the treatment of muscle wasting. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

IPC Classes  ?

• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

Disclosed herein are methods of treatments with a telomerase-mediated telomere-targeting drug, 6-thio-2′-deoxyguanosine (6-thio-dG), checkpoint inhibitors and/or radiation therapy for treating cancers. eads to tumor regression in innate and adaptive immune-dependent manners in syngeneic and humanized mouse cancer models.

IPC Classes  ?

• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61N 5/00 - Radiation therapy
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Disclosures herein are directed to methods and compositions for predicting high- and low-risk for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease (NAFLD). Provided herein are methods of identifying the NAFLD as indolent-, progressive, or advanced-NAFLD. Based on the results achieved from the methods and compositions disclosed herein, non-alcoholic fatty liver disease patients can be classified into a prognostic risk group, which enables early diagnosis and prevention of hepatocellular carcinoma and other lethal complications. Methods and compositions disclosed herein substantially improve the poor prognosis of subjects having or at risk for hepatocellular carcinoma.

IPC Classes  ?

• G01N 30/72 - Mass spectrometers
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Provided herein are engineered insulin polypeptide that exhibit disrupted cross-β fibrillation and pharmaceutical compositions comprising the polypeptides. The disclosure also provides are methods for making the insulin polypeptide. Also included are methods of using the pharmaceutical compositions to treat diabetes and hyperglycemia.

IPC Classes  ?

• C07K 14/62 - Insulins
• A61K 38/28 - Insulins
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Provided herein are composition and methods for editing of CaMKIlδ to reduce or prevent stress induction in human cells and mice.

Abstract

The present invention relates to novel small molecule FGF14:NAV1.6 channel complex protein-protein interaction modulators of the general structure according to Formula (I), and the preparation and use thereof:

Abstract

Embodiments of the instant disclosure relate to novel antiviral compositions and methods for treating viral infections. In accordance with these embodiments, antiviral compositions can include at least one mRNA encoding for a TRIM7 protein encapsulated into a lipid nanoparticle (LNP). In other embodiments, methods of making antiviral compositions are disclosed as well as methods of administering a composition having at least one mRNA encoding for a TRIM7 protein encapsulated into LNP into a subject.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• A61K 9/51 - Nanocapsules
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present disclosure generally relates to compositions and methods for treating cancer, particularly certain treatment resistant cancers. Various aspects include providing a combination of a receptor tyrosine kinase (RTK) inhibitor and an SUMOylation inhibitor for the treatment of cancer. Also described are treatment of cancers resistant or at risk of becoming resistant to RTK inhibition.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation

Abstract

The present disclosure generally relates to compositions and methods for treating cancer, particularly certain treatment resistant cancers. Aspects include providing a combination of a receptor tyrosine kinase (RTK) inhibitor and an Anaplastic Lymphoma Kinase (ALK) inhibitor for the treatment of cancer. Aspects provide for treatment of cancers resistant or at risk of becoming resistant to RTK inhibition, including those that do would not normally be treated with ALK inhibition.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 35/00 - Antineoplastic agents
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

11+) inhomogeneity through generation of a corrected homogeneous image with desired contrast based on the plurality of intermediate complex images.

IPC Classes  ?

• G01R 33/36 - Electrical details, e.g. matching or coupling of the coil to the receiver
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G01S 7/52 - Details of systems according to groups , , of systems according to group
• A61B 8/14 - Echo-tomography

Abstract

Systems, methods, and devices include a reconfigurable multi-purpose surgical tool with a housing having a plurality of portions for a plurality of surgical tools, such as a cautery tool, a scalpel tool, and/or a forceps tool. A first portion of the housing can house a first surgical tool. The first surgical tool is converted between an in-use configuration and a stored configuration. The stored configuration includes a first surgical tool portion of the first surgical tool being at least partially contained by the housing. The in-use configuration being when the first surgical tool portion is at least partially exposed from the housing. A second portion of the housing partially houses a second surgical tool. The second surgical tool includes another in-use configuration with the second surgical tool at least partially exposed from the housing. A third portion of the housing at least partially houses a third surgical tool.

IPC Classes  ?

• A61B 18/14 - Probes or electrodes therefor
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body

Abstract

The present disclosure includes methods, apparatuses, and systems for three-dimensional phenotyping and physiologic characterization of brain lesions and tissue encompassing one or more enlarged boundaries surrounding the brain lesion to study the metabolic and physiologic profiles from tissue within and around lesions and their impacts on lesion shape and surface texture. The non-invasive biomarker blood-oxygen their impacts on lesion shape and surface texture. The non-invasive biomarker blood-oxygen-level-dependant (BOLD) slope was used to metabolically characterize lesions. Metabolically active lesions with more intact tissue and myelin architecture have more symmetrical shapes and more complex surface textures compared to metabolically inactive lesions with less intact tissue and myelin architecture. The association of lesions' shapes and surface features with their metabolic signatures aid in the translation of MRI data to clinical management by providing information related to metabolic activity, lesion age, and risk for disease reactivation and self-repair.

IPC Classes  ?

• G06T 7/00 - Image analysis
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06T 7/11 - Region-based segmentation
• G06T 7/149 - SegmentationEdge detection involving deformable models, e.g. active contour models

Abstract

Isolated or recombinant anti-LILRB2 monoclonal antibodies are provided. In some embodiments, the antibodies herein can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as Alzheimer's Disease. In further aspects, the LILRB2-binding antibodies can affect cellular signaling mediated through at least the oA and PS-mediated TREM2 and LILRB2 co-ligation signaling pathway and can be used to modulate microglia function.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

IPC Classes  ?

• C07C 321/14 - Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
• A61K 9/51 - Nanocapsules
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07C 323/52 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
• C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Abstract

Systems, methods, and devices include a heat transfer treatment device which uses hypothermia to slow and/or halt brain tumor growth (e.g., "cytostatic hypothermia"). These fully and/or partially implantable device(s) use a physics-based approach to treat the targeted cells in a patient. The heat transfer treatment device includes a body portion having a top surface and a bottom surface. A cooling probe array with a particular probe geometry design includes a plurality of cooling probes extending at least partly from the bottom surface. The heat transfer treatment device also includes an injection delivery system having a port, a reservoir fluidly coupled to the port, and/or a delivery tunnel fluidly coupled to the reservoir and extending through the body portion out the bottom surface. As such, the heat transfer treatment device provides hypothermia treatment concomitantly with chemotherapy and immunotherapy.

IPC Classes  ?

• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body

Abstract

Provided herein are anti-CD5L monoclonal antibodies. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

This disclosure relates to nucleic acid constructs for expression of Solute Carrier Family 6 Members (SLC6A8) protein, and viral vectors comprising said constructs useful for the treatment of cerebral creatine transporter deficiency (CCDS1 ). Also provided are methods and uses of the vectors disclosed herein for the treatment of CCDS1.

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 3/00 - Drugs for disorders of the metabolism
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/86 - Viral vectors
• C12N 15/864 - Parvoviral vectors

Abstract

Compositions and methods for treatment of one or more metabolic disorders in a subject are provided. Disclosures herein are directed to compositions comprising a beta-adrenergic receptor (ADRB1) antagonist and a beta-3 adrenergic receptor (ADRB3) agonist and methods of using such compositions for treating, preventing, and/or ameliorating a metabolic disease or a metabolic disease condition.

IPC Classes  ?

• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/426 - 1,3-Thiazoles
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TfR protein, e.g., a mammalian TfR or human TfR, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 49/00 - Preparations for testing in vivo
• C07K 14/725 - T-cell receptors

Abstract

The present disclosure is directed to neural interface devices and methods that accesses the subarachnoid space to enable minimally invasive modulation and recording of neural structures. Exemplary embodiments may comprise an implantable pulse generator and a microelectrode catheter. In particular embodiments, the microelectrode catheter comprises one or more stimulating and recording electrodes. Exemplary embodiments may also include methods comprising performing a lumbar puncture to access the spinal subarachnoid space and advancing microcatheter through the spinal subarachnoid space.

IPC Classes  ?

• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61M 25/00 - CathetersHollow probes
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments etc., that specifically bind a TREM2 protein or a TREM2 protein epitope, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to SLC6A1 loss and/or misfunction. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for a GAT1 polypeptide.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Goods & Services

Clothing, namely, tops as clothing, shirts, t-shirts, long-sleeved shirts, athletic shirts, polo shirts, dress shirts, collared shirts, tank tops, sweatshirts, hooded sweatshirts, hoodies, pullovers, fleece pullovers, fleece tops, hats, baseball caps, bucket hats; headwear Entertainment services, namely, organizing and conducting collegiate athletic competitions; providing collegiate athletic and sporting events; providing information in the field of collegiate sports and collegiate athletic competitions; providing online videos featuring collegiate sports and collegiate athletic competitions, not downloadable; organizing community sporting and cultural events

Abstract

The described invention is directed toward pharmaceutical compositions and methods of using 6-mercaptopurine ribosides and analogues thereof for the treatment of cancer and other hyperproliferative diseases. The described compounds can be converted into telomere substrates in vivo and can be recognized by telomerase for incorporation into telomeres of telomerase active cells, leading to induction of cell death of the telomerase active cells.

IPC Classes  ?

• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Provided herein are multivalent FAP-targeting radiopharmaceutical compositions built upon a stable and neutral bifunctional chelator for enhanced specific binding and tumor retention of FAP-targeted theranostics. Also provided are method for using these compositions.

IPC Classes  ?

• C07F 1/08 - Copper compounds
• A61K 51/04 - Organic compounds
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed herein are serotonin (5-hydroxytryptamine) 5-HT2A receptor and/or 5-HT2C receptor allosteric modulators, the preparation thereof and use thereof.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present disclosure in various aspects provides methods for making pharmaceutical compositions for treating neurodegenerative diseases (e.g., demyelinating diseases), such as but not limited to multiple sclerosis, neuromyelitis optica, and transverse myelitis. The pharmaceutical compositions impact specific antibody-mediated processes involved in the biology of neurodegenerative disease. In certain aspects, the disclosure provides pharmaceutical compositions for treating neurodegenerative disease, which are based on inhibiting the action of pathologic antibodies, or alternatively providing antibodies to stimulate neuroprotection or repair processes.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Disclosed herein are compositions comprising recombinant arenavirus monoclonal antibodies and antigen-binding fragments thereof, as well as therapeutic methods using the antibodies. In some embodiments, the antibodies provide pan-arenavirus protection against a number of arenavirus types and strains.

IPC Classes  ?

• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

A computer-implemented technique for deep distilling is disclosed. The technique includes obtaining training samples for training an artificial neural network: determining multiple sub concepts within the training samples such that a minimum number of linearly separable sub concept regions are formed: processing the sub concepts to obtain neurons that form an output of the neural network: organizing the neurons into one or more groups with similar connectivity patterns: and interpreting the neurons as implementing logical functions.

IPC Classes  ?

• G06N 3/08 - Learning methods

Abstract

The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to CSTB loss and/or misfunction. The methods and compositions of the present disclosure include rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules encoding CSTB polypeptides.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to SLC13A5 loss, misfunction and/or deficiency, including neurological disorders, diseases, and conditions such as epileptic encephalopathy. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for an SLC13A5 polypeptide.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 15/86 - Viral vectors

Abstract

Modified human renin, nucleic acid containing modified human renin, and methods of using modified human renin are provided. The modified human renin contains one or more amino acid substitutions selected from the group consisting of L147I, R148H, I203V, and L290V. Aspects of the methods include contacting a cell that expresses: (i) the engineered POI comprising a first POI domain and a mouse renin cleavage site; and (ii) a modified human renin comprising amino acid substitutions L147I, R148H, I203V, and L290V with aliskiren to modulate the activity of the engineered POI.

IPC Classes  ?

• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/86 - Viral vectors
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes

Abstract

Disclosed herein are compounds of the formula (I) or (II) wherein the variables are defined herein. Also provided are methods of manufacturing and pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as PARP1 inhibitors. In some aspects, the present disclosure provides methods wherein the compounds and compositions described herein are used for the treatment of diseases and disorders, such as cancer. Disclosed herein are compounds of the formula (I) or (II) wherein the variables are defined herein. Also provided are methods of manufacturing and pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as PARP1 inhibitors. In some aspects, the present disclosure provides methods wherein the compounds and compositions described herein are used for the treatment of diseases and disorders, such as cancer.

IPC Classes  ?

• C07D 493/06 - Peri-condensed systems
• A61K 31/365 - Lactones
• A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07D 307/77 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems

Abstract

The present disclosure generally relates to compositions and methods for treating neurodegenerative disease or brain injury or providing protection from neural degeneration and/or neural injury. Aspects of the method comprise administering a MAP4K inhibitor, wherein the MAP4K inhibitor is a Citron homology domain (CNH) or a CNH-containing truncation of MAP4K4, MAP4K6, or MAP4K7, a gRNA comprising a target sequence of MAP4K4, MAP4K6, or MAP4K7, a shRNA comprising a target sequence of MAP4K4, MAP4K6, or MAP4K7, or a chemical inhibitor. Vectors and isolated nucleic acids comprising the MAP4K inhibitors are also described.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Disclosures herein are directed to compositions comprising single guide RNA (sgRNA) designed for a CRISPR/Cas9 system and method of using thereof for preventing, ameliorating or treating one or more cardiomyopathies. For example, provided herein are composition and methods for the correction of dilated cardiomyopathy by precise genomic editing of RBM20 mutations in human cells and mice.

IPC Classes  ?

• A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/86 - Viral vectors

Abstract

The invention describes a method to synthesize a divinyl- and diepoxy-substituted dibenzocyclooctanes, thereby providing a curative that can undergo a twist-boat to chair isomerization at elevated temperatures. The synthetic approach can be applied to a variety of thermosetting resins that can be crosslinked with the curative to form a polymer having a tunable coefficient of thermal expansion.

IPC Classes  ?

• C07C 41/06 - Preparation of ethers by addition of compounds to unsaturated compounds by addition of organic compounds only

Abstract

In some aspects, the present disclosure provides compositions of lipid nanoparticles useful for the delivery of large RNAs including mRNAs. These compositions may include a cationic ionizable lipid, a phospholipid, a PEGylated lipid, and a steroid including using less of a cationic ionizable lipid than compositions with shorter nucleic acids. These compositions may be used to treat a disease or disorder for which the delivery of an mRNA is therapeutically effective.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Systems and methods are provided for a gut microbiome signature for cancers, including prostate cancer (PCa), using a prostate specific antigen (PSA)-independent, gut microbiome-based PCa biomarker, which can be used for diagnosis, suitability' for screening, treatment decisions and as part of a treatment method.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to novel small molecule activators of Sirt6, for example, compounds of the general Formula (I), their methods and use for the treatment of various human diseases such as cancer, inflammatory diseases, neurodegenerative diseases, and infectious diseases: The present invention relates to novel small molecule activators of Sirt6, for example, compounds of the general Formula (I), their methods and use for the treatment of various human diseases such as cancer, inflammatory diseases, neurodegenerative diseases, and infectious diseases:

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• C07D 498/04 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

The present disclosure provides methods and compositions for the treatment of Angelman Syndrome The methods and compositions of the present disclosure comprise isolated nucleic acid molecules, rAAV vectors and rAAV viral vectors comprising polynucleotide sequences encoding for short hairpin RNA (shRNA) molecules directed against UBE3A-ATS.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present disclosure generally relates to compositions and methods comprising colon-specific immune niche. Further provided is a method of treating a condition or disease of large intestinal tract tissue using the colon-specific immune niche. A method of making a colon-specific immune niche is also described.

IPC Classes  ?

• A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
• A61P 37/04 - Immunostimulants
• C08F 2/18 - Suspension polymerisation
• C08F 265/06 - Polymerisation of acrylate or methacrylate esters on to polymers thereof
• C08G 63/91 - Polymers modified by chemical after-treatment
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

Embodiments of the present disclosure provide systems and methods for anesthesia depth monitoring. One such method comprises obtaining baseline EEG data of a subject prior to sedation; obtaining time-series EEG data of the subject after initiation of sedation; identifying loss of consciousness (LOC) of the subject; generating profiles segmented from the time-series EEG data that correspond to the LOC of the subject and sedation levels of the subject before and after LOC; training an AI sedation model associated with the subject using the generated profiles, wherein the AI sedation model is trained to determine a sedation level of the subject based upon a profile segmented from the time-series EEG data of the subject; determining a current sedation level of the subject based upon a current profile segmented from the time-series EEG data; and/or providing an indication of a comparison of the current sedation level with a target sedation level.

IPC Classes  ?

• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/369 - Electroencephalography [EEG]
• G06N 20/00 - Machine learning
• G06N 3/08 - Learning methods
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Provided herein is a molecular sorbent based on copper that provides high-purity separation, such as separation of ethylene from ethylene-ethane mixtures and propylene from propylene-propane mixtures. Further provided herein are compositions thereof, methods of manufacturing these, and methods of use thereof.

IPC Classes  ?

• C07F 5/05 - Cyclic compounds having at least one ring containing boron but no carbon in the ring
• B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
• C07C 7/11 - Purification, separation or stabilisation of hydrocarbonsUse of additives by absorption, i.e. purification or separation of gaseous hydrocarbons with the aid of liquids
• C07C 7/12 - Purification, separation or stabilisation of hydrocarbonsUse of additives by adsorption, i.e. purification or separation of hydrocarbons with the aid of solids, e.g. with ion-exchangers

Abstract

The present disclosure describes various embodiments of systems, apparatuses, and methods for predicting an onset of a seizure by identifying a pro-octal state in advance of the seizure, potentially hours prior to seizure onset. One such method comprise acquiring, by a computing device, electroencephalography (EEG)-based features from brain activity electrical recordings of an individual; inputting, by the computing device, the EEG-based features into a deep neural network-based classifier; classifying, by the computing device using the deep neural network-based classifier, the EEG-based features to a real-valued principal dimension; and/or based on a value of the real-valued principal dimension, generating, by the computing device, a prediction of a seizure onset pro-ictal event.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/293 - Invasive
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Systems, methods, and devices include a multifaceted artificial intelligence (AI)-based radiomics model for predicting lymph node malignancy. Creating training data includes labelling instances from CT fused with PET training data as malignant or benign. The multifaceted AI-based radiomics models include a neural network architecture fused with a multi-objective radiomics model. The system includes a hybrid PET and diagnostic CT fused model and one or more disease specific CT-only models (e.g., for oropharynx, larynx, and/or hypopharynx). The methods also calculate prediction uncertainty values associated with lymph node malignancy predictions, which can be presented at a user interface of a computing device. The methods described use any medical imaging modality as input to identify malignant lymph nodes across diverse anatomical sites. The model allows the user to input a given lymph node, present on any number of imaging modalities, and produces a malignancy probability along with an uncertainty estimate of that prediction.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

in vitroin vitro culture systems for producing the stem cells.

Abstract

Provided here are compositions and method for use in development of interspecies chimera for research and medical purpose. The compositions include engineered stem cells and blastocysts that are defective in the "retinoic acid-inducible gene I (RIG-I)-like receptor" (RLR) signaling pathway.

IPC Classes  ?

• A01K 67/0276 - Knock-out vertebrates
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

Provided herein are antibodies binding to CHI3L1 and the uses of the antibodies in detecting and treating cancer and for treating hepatotoxicity.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

A novel method of geometric isometry based antigen-specific TCR alignment (GIANA) is described herein. GIANA is an antigen-specific TCR clustering method that is able to efficiently handle tens of millions of sequences. GIANA achieved higher sensitivity and precision than all existing methods, and is able to retrieve TCRs specific to known antigens with high accuracy. The ultra-large-scale TCR clustering and fast query of novel samples also enabled a novel reference-based repertoire classification framework. GIANA can also analyze single cell RNA-seq data with TCR regions solved, and it is possible to query TCRs from unknown data against the large database of TCR repertoire samples in the public domain, and provide new insights over shared antigen-specificity. GIANA is applicable to cluster or query large B cell receptor sequencing data as well.

IPC Classes  ?

• G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
• G16B 40/20 - Supervised data analysis
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present disclosure describes the use of immune modulators to promote nerve growth and regeneration, particularly in the context of nerve deficit stemming from trauma and disease. In particular, the disclosure provides for the use of CXCR4 antagonists, STAT3 activators, and an agent that increases levels of nitric oxide, either alone or in any combination of these drugs, in surgery performed to treat nerve deficit conditions, especially peripheral nerve deficit conditions caused by cut injury or tear injury, the method especially useful in bridging nerve gaps of 3 cm or longer.

IPC Classes  ?

• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
• A61K 38/20 - Interleukins
• A61L 27/24 - Collagen

Abstract

Provided herein are pharmaceutical compositions that inhibit or activate cleavage of Angiopoietin-2 by Cathepsin K and method of treatment of sepsis and cancer using the disclosed compositions.

IPC Classes  ?

• A61K 31/10 - SulfidesSulfoxidesSulfones
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• A61K 31/03 - Halogenated hydrocarbons carbocyclic aromatic
• A61K 31/04 - Nitro compounds
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

Systems, methods, and devices perform a fluorescence microscopy procedure by providing a confocally-sectioned live projection image of a sample. The system includes a camera and a light source operable to perform a focal sweep across a portion of a sample. A subset portion of fluorescence light emitted from the sample is shifted over the camera with a galvo scanner, with the camera operating in a rolling shutter mode the subset portion of the fluorescence light is detected by a subset chip region of the camera as a confocal projection. This generates a live projection of a subsection of the sample (e.g., at a selected focal depth) under a selectable viewing angle. Moreover, a live projection of the subset portion of the fluorescence light is presented as a viewable image for observation. The techniques are used with lattice light sheet microscopes (LLSM)s or oblique plane microscopes (OPM)s.

IPC Classes  ?

• G02B 21/36 - Microscopes arranged for photographic purposes or projection purposes
• G02B 21/06 - Means for illuminating specimen
• G06T 7/00 - Image analysis

Abstract

The present disclosure provides in part an antisense oligonucleotide strategy to increase levels of polycystin 1 and/or polycystin 2 (PKD1 and/or PKD2). By targeting and inhibiting regulatory elements of the 3' UTR of PKD1 mRNA and/or PKD2 mRNA, compositions of the present disclosure are able to de-repress PKD1 and/or PKD2 mRNA and increase expression of PKD1 and/or PKD2 protein. Further methods are provided for increasing PKD1 and/or PKD2 expression in cells in vitro or in vivo as well as methods of treating autosomal dominant polycystic kidney disease using the antisense oligonucleotides provided herein.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The disclosed technology relates to a computer-implemented method for predicting T cell receptor (TCR) binding specificities towards T cell antigen targets (namely, peptide-major histocompatibility complexes, pMHCs), and a set of extensions of this method, include prediction of immune-related adverse events (irAEs) using a machine learning model. The method involves obtaining genomic and proteomic data from patients, determining TCR and pMHC sequences by analyzing these data, and predicting binding interactions between T cell antigens and the TCRs. The extensions include: (a) a transfer learning model for improving the predictive performance of a pre-trained TCR-antigen binding model as a foundation model, to enhance prediction for a specific pMHC, (b) a biomarker metric defined based on the output of the TCR-pMHC binding prediction method, for diagnosis, prognosis and response prediction purposes, (c) a method, based on the output of the TCR-pMHC binding prediction method, to select optimal antigens for tumor vaccines.

IPC Classes  ?

• G16B 20/30 - Detection of binding sites or motifs
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Abstract

The present disclosure relates to an oncolytic virus and methods of using such to treat cancer. The methods may advantageously involve further treating with at least a first DNA damaging agent, such as radiation or a chemotherapeutic agent. In some embodiments, the oncolytic virus is an oncolytic herpes simplex virus (oHSV) that optionally has been engineered to expression a portion of CD44, in particular the extracellular domain of CD44.

IPC Classes  ?

• A61K 35/763 - Herpes virus
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 15/86 - Viral vectors

Abstract

An apparatus includes a body extending along a first axis, the body including a first end and a second end opposite the first end, a first connector coupled with the body proximate the first end, the first connector defining a first opening configured to receive a portion of a working channel of a bronchoscope, a second connector coupled with the body proximate the second end and extending from the body at an angle relative to the first axis, the angle being greater than 0 degrees and less than 90 degrees. The second connector defines a second opening configured to receive a portion of an endotracheal tube while a portion of the bronchoscope is positioned within the endotracheal tube and a gap configured to allow the endotracheal tube to translate from outside the second opening to inside the second opening.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor

Abstract

Apparatus and methods for clot burst pressure measurement are disclosed herein. Specific embodiments include a pump, a pressure measurement device, and a container comprising an inlet, an outlet and an orifice. In particular embodiments, the pump is coupled to the inlet of the container, the pressure measurement device is coupled to the outlet of the container, and the orifice is configured to retain a fluid extending across the orifice.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01D 21/00 - Measuring or testing not otherwise provided for
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood

Abstract

The innate immune sensing STING pathway has emerged as a potential therapeutic target to boost antitumor immune responses. STING resides in the cytoplasm, and its agonists, such as cGAMP, are dinucleotides that are difficult to deliver intracellularly. Disclosed herein is a microbubble-based platform (Microbubble (MB)-assisted UltraSound (US)-guided Immunotherapy of Cancer (MUSIC)) that can be used for targeted activation of STING, such as for treatment of primary and metastatic tumors.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61N 7/00 - Ultrasound therapy

Abstract

The present disclosure provides methods and compositions for the treatment of tauopathies, such as, for example, Alzheimer's Disease or FTDP-17. The methods and compositions of the present disclosure comprise isolated nucleic acid molecules, rAAV vectors and rAAV viral vectors comprising polynucleotide sequences encoding for artificial micro RNAs (amiRNAs) directed against MAPT.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/86 - Viral vectors